Philips, Accenture test brain-controlled
system for ALS patients
Send a link to a friend
[August 06, 2014]
By Christina Farr
SAN FRANCISCO (Reuters) - The Netherlands’
Royal Philips and IT consultancy Accenture are developing software to
help people with neurodegenerative diseases like amyotrophic lateral
sclerosis, commonly known as Lou Gehrig's disease, live more
independently.
|
The companies said they have built a trial application that lets
patients with ALS, a disease that diminishes muscle action, issue
"brain commands" to turn lights on and off or send an alert to a
doctor.
The software works by connecting a wireless headset developed by
Emotiv, a San Francisco-based startup, to a wearable device. Emotiv
says its headset can read brain waves and translate them into
readable data, which is then used to issue commands to Philips’
existing connected products such as "smart" TVs and lighting
systems.
Wearers also can issue commands using their voice or eyes, and the
app lets patients store pre-recorded messages in their own voice.
Accenture and Philips jointly developed the software that connects
the various technologies.
It marks the latest in a string of partnerships between information
technology and medical firms to develop products for people with
chronic conditions. In July, Google struck a deal with Swiss drug
maker Novartis to develop a smart contact lens that can monitor
blood-sugar levels, which would particularly be useful to diabetics.
Accenture and Philips stress their app is a "proof of concept" but
said they have tested it with patients. They are open to
conversations with other consumer technology providers, like Apple
and Google, and are seeking partnerships with caregiver
associations.
"We are looking for our next set of partners," Thibaut Sevestre, who
heads innovation for Philips' IT architecture and platforms, said in
an interview with Reuters.
"Patients find that they can do less and less by themselves, until
they are completely paralyzed," Sevestre added. "So we asked, 'How
can we help them regain control?'"
Philips stressed, however, that commercial viability was not yet
established. "At this point, we are exploring this concept for the
sake of innovation and research. We’ll continue to collect feedback
and explore its potential, but we cannot confirm any commercial
development at this time, nor any plans to test this on patients in
the future," a Philips spokesman said in a statement.
[to top of second column] |
The app is not designed as a monitoring tool that can inform doctors
of a patient's current state. Instead, Sevestre said, it aimed to
give people back "some capabilities they’ve lost." In the later
stages of ALS, people will sometimes be rendered completely
paralyzed but retain brain functions.
The project kicked off in May after several Accenture employees
pitched the idea. A key employee died in the downing of a Malaysia
Airlines plane over eastern Ukraine in July.
Throughout the summer, Accenture conducted interviews and tests with
ALS patients at its research lab in San Jose, California. Some
400,000 people suffer from the disease, but Accenture’s chief
technology officer, Paul Daugherty, said the goal is to adapt the
application to a broad spectrum of patients.
The firms estimate their app can eventually benefit some 40 million
people.
(Reporting by Christina Farr; Editing by Paul Simao)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|